- Home
- ACCS vs VTGN Comparison
ACCS vs VTGN Comparison
Compare ACCS & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$6.03
HOLD
Current Price
$0.54
Company Overview
Basic Information| Metric | ACCS | VTGN |
|---|---|---|
| Founded | 1988 | 1998 |
| Country | United States | United States |
| Employees | 91 | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7M | 24.1M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | ACCS | VTGN |
|---|---|---|
| Price | $6.03 | $0.54 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $14.00 | $0.90 |
| AVG Volume (30 Days) | 11.4K | ★ 717.7K |
| Earning Date | 05-13-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ N/A | N/A |
| Revenue This Year | $7.40 | $124.49 |
| Revenue Next Year | $8.75 | $353.99 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.99 | $0.43 |
| 52 Week High | $13.35 | $5.14 |
Technical Indicators
Market Signals| Indicator | ACCS | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 31.22 | 37.69 |
| Support Level | N/A | $0.54 |
| Resistance Level | $8.76 | $0.67 |
| Average True Range (ATR) | 0.37 | 0.05 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 0.95 | 1.55 |
Price Performance
Historical Comparison ACCS
VTGN
About ACCS ACCESS Newswire Inc.
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.